tetano
Editor, Senior Moderator
Clin Infect Dis
. 2020 Dec 10;ciaa1804.
doi: 10.1093/cid/ciaa1804. Online ahead of print.
Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey
Kristina L Bajema[SUP] 1 [/SUP], F Scott Dahlgren[SUP] 1 [/SUP], Travis W Lim[SUP] 1 [/SUP], Nicolette Bestul[SUP] 1 [/SUP], Holly M Biggs[SUP] 1 [/SUP], Jacqueline E Tate[SUP] 1 [/SUP], Claudio Owusu[SUP] 1 [/SUP], Christine M Szablewski[SUP] 1 2 [/SUP], Cherie Drenzek[SUP] 2 [/SUP], Jan Drobeniuc[SUP] 1 [/SUP], Vera Semenova[SUP] 1 [/SUP], Han Li[SUP] 1 [/SUP], Peter Browning[SUP] 1 [/SUP], Rita Desai[SUP] 1 [/SUP], Monica Epperson[SUP] 1 [/SUP], Lily T Jia[SUP] 1 [/SUP], Natalie J Thornburg[SUP] 1 [/SUP], Chris Edens[SUP] 1 [/SUP], Alicia M Fry[SUP] 1 [/SUP], Aron J Hall[SUP] 1 [/SUP], Jarad Schiffer[SUP] 1 [/SUP], Fiona P Havers[SUP] 1 [/SUP]
Affiliations
Abstract
We compared severe acute respiratory syndrome-related coronavirus-2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April-May 2020 and found these two estimates to be similar (4.94% versus 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.
Keywords: Convenience sampling; Coronavirus disease 2019 (COVID-19); Seroprevalence; Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2).
. 2020 Dec 10;ciaa1804.
doi: 10.1093/cid/ciaa1804. Online ahead of print.
Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey
Kristina L Bajema[SUP] 1 [/SUP], F Scott Dahlgren[SUP] 1 [/SUP], Travis W Lim[SUP] 1 [/SUP], Nicolette Bestul[SUP] 1 [/SUP], Holly M Biggs[SUP] 1 [/SUP], Jacqueline E Tate[SUP] 1 [/SUP], Claudio Owusu[SUP] 1 [/SUP], Christine M Szablewski[SUP] 1 2 [/SUP], Cherie Drenzek[SUP] 2 [/SUP], Jan Drobeniuc[SUP] 1 [/SUP], Vera Semenova[SUP] 1 [/SUP], Han Li[SUP] 1 [/SUP], Peter Browning[SUP] 1 [/SUP], Rita Desai[SUP] 1 [/SUP], Monica Epperson[SUP] 1 [/SUP], Lily T Jia[SUP] 1 [/SUP], Natalie J Thornburg[SUP] 1 [/SUP], Chris Edens[SUP] 1 [/SUP], Alicia M Fry[SUP] 1 [/SUP], Aron J Hall[SUP] 1 [/SUP], Jarad Schiffer[SUP] 1 [/SUP], Fiona P Havers[SUP] 1 [/SUP]
Affiliations
- PMID: 33300579
- DOI: 10.1093/cid/ciaa1804
Abstract
We compared severe acute respiratory syndrome-related coronavirus-2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April-May 2020 and found these two estimates to be similar (4.94% versus 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.
Keywords: Convenience sampling; Coronavirus disease 2019 (COVID-19); Seroprevalence; Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2).